Venetoclax
Hematopoietic And Lymphoid System Neoplasm
Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Jacqueline Garcia, MD
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07148180CT.gov A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax | — | Recruiting | — | — | — |
NCT05753501CT.gov Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT05371054CT.gov Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | — | Completed | — | — | — |
NCT04926285CT.gov Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT04588922CT.gov Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03557619CT.gov A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies | — | Recruiting | — | — | — |
NCT03471260CT.gov Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | — | Recruiting | — | — | — |
NCT03082209CT.gov A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Venetoclax (this asset) | Jacqueline Garcia, MD | P1/2 | B · 57 |
| Adriamycin | OHSU Knight Cancer Institute | P4 | BBB |
| Dexasone | City of Hope Medical Center | P3 | BB |
| Teclistamab | Janssen Pharmaceutical K.K. | P2 | BB |
| Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf) | Gamida Cell ltd | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Bortezomib | OHSU Knight Cancer Institute | P4 | BB |
| Etoposide | Ciusss de L'Est de l'Île de Montréal | P2 | BB |
| Pembrolizumab | Vividion Therapeutics, Inc. | P3 | BB |
+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort
Other indications for Venetoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 70 |
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Chronic Myelomonocytic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinOHSU Knight Cancer InstituteBBB
- DexasoneCity of Hope Medical CenterBB
- TeclistamabJanssen Pharmaceutical K.K.BB
- Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdBB
- CyclophosphamideNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Venetoclax in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/venetoclax-hematopoietic-and-lymphoid-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →